Eirsciences
About Eirsciences
This contract research organization provides immunogenicity assessment services, including epitope identification, immunogenicity risk assessment, and deimmunization of proteins. Their platform helps biopharmaceutical companies reduce drug failure risk and accelerate drug development by optimizing immunogenicity.
```xml <problem> Biopharmaceutical companies face challenges in predicting and mitigating the immunogenicity of protein-based therapeutics, which can lead to adverse immune responses, reduced drug efficacy, and costly clinical trial failures. Identifying potential immunogenic regions (epitopes) within a protein sequence and assessing the overall immunogenicity risk is complex and requires specialized bioinformatics tools and expertise. Optimizing the sequence to reduce immunogenicity while maintaining therapeutic function is also a significant hurdle. </problem> <solution> Eir Sciences offers contract research services focused on immunogenicity assessment and optimization of biopharmaceuticals. Using advanced bioinformatics tools and algorithms, including their EIR::pred™, EIR::eval™, EIR::elim™, and EIR::opti™ technologies, they identify potential T-cell and B-cell epitopes within protein sequences. Their services include epitope identification, immunogenicity risk assessment, deimmunization of proteins by suggesting specific mutations to minimize immunogenicity, and immunogenicity optimization to enhance immune responses when desired. Eir Sciences supports biopharmaceutical companies in making informed decisions during drug development, reducing the risk of adverse immune reactions, and accelerating the development of safer and more effective protein-based therapeutics. </solution> <features> - **EIR::pred™:** Identifies potential immunogenic regions in proteins using epitope prediction and protein pattern recognition methods, including MHC class I & II and B-cell epitope prediction. - **EIR::eval™:** Provides immunogenicity predictions and calculates a combined risk score, customizable based on factors like ethnic variations in MHC molecules. - **EIR::elim™:** Analyzes the immunogenicity risk profile of a protein and suggests specific mutations to minimize the risk of evoking an immune response, using a Monte Carlo-like optimization process. - **EIR::opti™:** Analyzes the immunogenicity profile and suggests mutations to maximize the immune response, also using a Monte Carlo-like optimization process. - Prediction of Cytotoxic T Lymphocytes (CTL) epitopes by predicting the interaction between peptides and the MHC class 1 molecule using the NetMHCpan method. - Prediction of Helper T cell epitopes (Th epitopes) by predicting the binding of peptides to the MHC class two complex using the NetMHCIIpan method. - Prediction of B-cell epitopes using DiscoTope, which combines amino acid statistics, spatial information, and surface exposure. </features> <target_audience> Eir Sciences primarily serves biopharmaceutical companies developing protein-based therapeutics, vaccines, and antibody-based drugs, as well as research institutions involved in protein engineering and immunology research. </target_audience> ```
What does Eirsciences do?
This contract research organization provides immunogenicity assessment services, including epitope identification, immunogenicity risk assessment, and deimmunization of proteins. Their platform helps biopharmaceutical companies reduce drug failure risk and accelerate drug development by optimizing immunogenicity.
When was Eirsciences founded?
Eirsciences was founded in 2024.
- Founded
- 2024 0